RIPTAC
VantAI and Halda Strike $1B+ AI-Driven Partnership on ‘Hold-and-Kill’ Drugs
VantAI; Halda Therapeutics; RIPTAC drugs; hold-and-kill; AI drug discovery; target-effector pairs; oncology; immunology; regulated induced proximity targeting chimeras; $1 billion deal
Halda Therapeutics Secures $126M to Advance ‘Hold and Kill’ Solid Tumor Drugs into Clinical Trials
Halda Therapeutics, RIPTAC therapeutics, cancer treatment, solid tumors, prostate cancer, breast cancer, clinical trials, Series B extension financing